I.v. therapy: the legislative and regulatory arena.

Area of Science:

• Healthcare Policy
• Medical Regulation
• Home Healthcare

Background:

• The Medicare Catastrophic Coverage Act of 1988 (MCCA) initially included provisions for home IV drug therapy.
• This inclusion brought significant attention to the complexities and challenges associated with home IV therapy.
• The MCCA was ultimately repealed, but the issues it raised remain relevant.

Purpose of the Study:

• To examine the regulatory and provider issues surrounding home IV drug therapy.
• To underscore the need for addressing these issues in current and future healthcare legislation.
• To analyze the impact of legislative attempts on home IV therapy services.

Main Methods:

• Policy analysis of the Medicare Catastrophic Coverage Act of 1988.
• Review of regulatory and provider responses to home IV therapy inclusion.
• Examination of legislative history and subsequent healthcare policy developments.

Main Results:

• The MCCA's inclusion of home IV therapy identified key regulatory and operational challenges.
• Despite legislative repeal, these identified issues persist and need ongoing attention.
• Provider and patient access to home IV therapy services were impacted by the legislative process.

Conclusions:

• The issues surrounding home IV drug therapy, initially highlighted by the MCCA, necessitate continued policy and regulatory focus.
• Current healthcare programs and future legislation must address the complexities of home IV therapy.
• Ensuring adequate and safe home IV therapy requires proactive policy development and stakeholder engagement.